SUDEEPPHRM vs VIVOBIOT: Stock Comparison
SUDEEP PHARMA is the larger company by market capitalisation. SUDEEP PHARMA shows a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SUDEEPPHRM leads 3; VIVOBIOT leads 0 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | SUDEEPPHRM | VIVOBIOT |
|---|---|---|
| Live Price | ₹1,003.3 | ₹13.63 |
| Day Change | 0.26% | -5.15% |
| Volume | 1.95 L | 20,155 |
| 52-Week High | ₹1,378 | ₹20.94 |
| 52-Week Low | ₹524.05 | ₹12.8 |
| Distance from 52W High | -27.19% | -34.91% |
Valuation
| Metric | SUDEEPPHRM | VIVOBIOT |
|---|---|---|
| Market Cap | ₹11,289 Cr | ₹30 Cr |
| P/E Ratio | 61.74x | — |
| P/B Ratio | 12.78x | — |
| EPS | ₹3.59 | ₹0.08 |
| Book Value | ₹79.51 | ₹41.98 |
| Dividend Yield | 0.15% | 0% |
Growth
| Metric | SUDEEPPHRM | VIVOBIOT |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | SUDEEPPHRM | VIVOBIOT |
|---|---|---|
| ROE | 19.41% | — |
| ROCE | 17.66% | — |
| Net Margin | 27.14% | 0% |
| Operating Margin | 36.7% | — |
| Debt to Equity | 0.17x | — |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SUDEEPPHRM | VIVOBIOT |
|---|---|---|
| Promoter Holding | 76.15% | 30.62%▼ 4.81 pp |
| FII Holding | 2.93%▲ 1.12 pp | 0% |
| DII Holding | 14.05%▼ 1.6 pp | 0% |
| Public Holding | 6.87%▲ 0.48 pp | 69.38%▲ 4.81 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SUDEEP PHARMA and VIVO BIO TECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.